ArticleGut2023
A novel peptide protects against diet-induced obesity by suppressing appetite and modulating the gut microbiota.
Article in Gut, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 77 citations in OpenAlex.
- Cancer-associated adipocytes: metabolic reprogramming, crosstalk and therapeutic implications in tumor progression.Signal transduction and targeted therapy · 2026Review
- Host-Microbiota Interactions in Obesity: Immune Metabolic Dysregulation.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Review
- Hemp Seed Protein-Derived Lipase Inhibitory Peptides Attenuate High-Fat Diet-Induced Obesity: Evidence from Intestinal Fat Digestion and Gut-Liver Axis Regulation.Foods (Basel, Switzerland) · 2026Article
- Study on the Mechanism ofBiomolecules · 2026Article
- Inhaling Eugenol Inhibits NAFLD by Activating the Hepatic Ectopic Olfactory Receptor Olfr544 and Modulating the Gut Microbiota.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Genetic variance in the murine defensin locus modulates glucose homeostasis.The EMBO journal · 2025Article
- The Effects of High-Fat Diet on the Molecular Pathways in Cardiac Tissue: A Systematic Review of In Vivo Rodent Studies and Integrated Bioinformatic Analysis.Biomedicines · 2025Review
- Development of cyclopeptide inhibitors specifically disrupting FXR-coactivator interaction in the intestine as a novel therapeutic strategy for MASH.Life metabolism · 2025Article
- RNA Modification in Metabolism.MedComm · 2025Review
- Anti-obesity peptides from food: Production, evaluation, sources, and commercialization.Comprehensive reviews in food science and food safety · 2025Review
- Therapeutic Strategies to Modulate Gut Microbial Health: Approaches for Chronic Metabolic Disorder Management.Metabolites · 2025Review
- Single-cell delineation of the microbiota-gut-brain axis: Probiotic intervention in Chd8 haploinsufficient mice.Cell genomics · 2025Article
- Brain-derived uroguanylin as a regulator of postprandial brown adipose tissue activation: a potential therapeutic approach for metabolic disorders.Frontiers in pharmacology · 2025Article
- Human microbiota-associated animal models: a review.Frontiers in cellular and infection microbiology · 2025Review
- Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice.Frontiers in pharmacology · 2025Article
- Puerarin affects adipose lipolysis and ameliorates obesity by gut microbiota.Frontiers in microbiology · 2025Article
- Psychometric evaluation of the Adult Eating Behavior Questionnaire and its relationship with body mass index among Chinese university students: a cross-sectional validation study.Frontiers in public health · 2025Article
- Immune Microenvironmental Differences Between Obese and Healthy People in a High-Altitude Hypoxic Environment.Journal of inflammation research · 2025Article
- The gut microbiota-derived metabolite indole-3-propionic acid enhances leptin sensitivity by targeting STAT3 against diet-induced obesity.Clinical and translational medicine · 2024Article
- Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe obesity epidemic and its metabolic complications continue to be a major global public health threat with limited effective treatments, especially drugs that can be taken orally. Peptides are a promising class of molecules that have gained increased interest for their applications in medicine and biotechnology. In this study, we focused on looking for peptides that can be administrated orally to treat obesity and exploring its mechanisms.
designHere, a 9-amino-acid peptide named D3 was designed and administered orally to germ-free (GF) mice and wild-type (WT) mice, rats and macaques. The effects of D3 on body weight and other basal metabolic parameters were evaluated. The effects of D3 on gut microbiota were evaluated using 16S rRNA amplicon sequencing. To identify and confirm the mechanisms of D3, transcriptome analysis of ileum and molecular approaches on three animal models were performed.
resultsA significant body weight reduction was observed both in WT (12%) and GF (9%) mice treated with D3. D3 ameliorated leptin resistance and upregulated the expression of uroguanylin (UGN), which suppresses appetite via the UGN-GUCY2C endocrine axis. Similar effects were also found in diet-induced obese rat and macaque models. Furthermore, the abundance of intestinal
conclusionOur results indicated that D3 is a novel drug candidate for counteracting diet-induced obesity as a non-toxic and bioactive peptide. Targeting the UGN-GUCY2C endocrine axis may represent a therapeutic strategy for the treatment of obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.